Slow-wave sleep and the risk of type 2 diabetes in humans.
Level 2 - randomized trial
Interventional experimental physiological study in humans.
PubMed 18172212 · doi:10.1073/pnas.0706446105
What was done
In young healthy adults, researchers performed all-night selective suppression of deep non-rapid eye movement sleep (slow-wave sleep, SWS) without altering total sleep duration. They evaluated delta spectral power and other EEG frequency bands, alongside measures of insulin sensitivity, insulin release, and glucose tolerance.
What was found
The abstract reports no numerical figures or confidence intervals. It states that selective SWS suppression led to marked decreases in insulin sensitivity without a compensatory rise in insulin secretion, impairing glucose tolerance. SWS suppression selectively reduced EEG delta spectral power without altering other frequency bands, and the magnitude of the decline in insulin sensitivity was strongly correlated with the magnitude of SWS reduction.
Why it matters
This study provides experimental evidence in humans that sleep architecture—specifically slow-wave sleep—directly regulates peripheral glucose homeostasis independently of total sleep duration. It suggests that age- or obesity-related declines in deep sleep could contribute to the development of type 2 diabetes.
Limits
The abstract does not state the sample size (n), participant demographics beyond "young healthy adults," or the duration of the intervention. Exact values, effect sizes, and p-values are not reported. The findings are restricted to acute laboratory-induced sleep disruption in healthy individuals, leaving the long-term clinical impact and applicability to populations with pre-existing metabolic disorders unmeasured.
Cited by
- supports Selective suppression of deep slow-wave sleep using acoustic stimuli, without altering total sleep duration, induces impaired glucose tolerance.